Zesheng Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zesheng Xu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Wanzhong Peng
Department 2 of Cardiology, Cangzhou Central Hospital, No. 16 Xinhua Road, Cangzhou 061000, Hebei, China
4 shared publicationsYonggang Yuan
Department of Cardiology Cangzhou Central Hospital of Tianjin Medical University Hebei China
3 shared publicationsYongxing Liu
Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei, China
2 shared publicationsAili Wang
Department 2 of Cardiology, Cangzhou Central Hospital, No. 16 Xinhua Road, Cangzhou 061000, Hebei, China
1 shared publicationBing Li
Department of Cardiology Cangzhou Central Hospital of Tianjin Medical University Hebei China
1 shared publicationFang Liu
Department 2 of Cardiology, Cangzhou Central Hospital, No. 16 Xinhua Road, Cangzhou, 061000 Hebei, China
1 shared publication
Latest Publications
- 13 December 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 79 (4) , 479-488
lncRNA Nuclear Factor of Activated T Cells Knockdown Alleviates Hypoxia/Reoxygenation-induced Cardiomyocyte Apoptosis by Upregulating HIF-1α Expression
Acute myocardial infarction (AMI) has become the most common cause of death in the developed countries. However, its pathogenesis is poorly understood. Increasing studies have revealed that lncRNAs are important modulators of AMI development. This study aimed to explore the function of lncRNA noncoding repressor of nuclear factor of activated T cells (NRON) in hypoxia/reoxygenation (H/R)-stimulated H9c2 cells. NRON expression in peripheral blood of AMI patients and H/R-stimulated H9c2 cells was measured by quantitative real-time polymerase chain reaction. H9c2 cells were transfected with si-NRON or cotransfected with si-NRON and si-hypoxia-inducible factor-1 alpha (HIF-1α). The viability and apoptosis of these cells were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay and flow cytometer, respectively. In addition, HIF-1α, AKT/mTOR signal pathways and ERK1/2 were detected by western blot. NRON knockdown in the myocardial infarction mouse model was conducted through adeno-associated virus injection, and cardiac function was evaluated by motion-mode echocardiography. The results showed that NRON was highly expressed in peripheral blood of AMI patients and H/R-stimulated H9c2 cells. NRON knockdown promoted cell viability and inhibited cell apoptosis of H/R-stimulated H9c2 cells. Meanwhile, NRON knockdown also significantly attenuated heart damage and improved cardiac function in an AMI mouse model. Furthermore, compared with si-normal control, NRON knockdown increased the levels of HIF-1α, p-AKT, p-mTOR, and p-ERK1/2. HIF-1α knockdown reversed the effects of NRON knockdown in H/R-stimulated-H9c2 cells damage. Overall, our study revealed that NRON knockdown alleviated H/R-induced cardiomyocyte apoptosis by upregulating HIF-1α expression, suggesting that NRON might be a novel therapeutic target for AMI.
- 13 December 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 79 (4) , 479-488
lncRNA Nuclear Factor of Activated T Cells Knockdown Alleviates Hypoxia/Reoxygenation-induced Cardiomyocyte Apoptosis by Upregulating HIF-1α Expression
Acute myocardial infarction (AMI) has become the most common cause of death in the developed countries. However, its pathogenesis is poorly understood. Increasing studies have revealed that lncRNAs are important modulators of AMI development. This study aimed to explore the function of lncRNA noncoding repressor of nuclear factor of activated T cells (NRON) in hypoxia/reoxygenation (H/R)-stimulated H9c2 cells. NRON expression in peripheral blood of AMI patients and H/R-stimulated H9c2 cells was measured by quantitative real-time polymerase chain reaction. H9c2 cells were transfected with si-NRON or cotransfected with si-NRON and si-hypoxia-inducible factor-1 alpha (HIF-1α). The viability and apoptosis of these cells were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay and flow cytometer, respectively. In addition, HIF-1α, AKT/mTOR signal pathways and ERK1/2 were detected by western blot. NRON knockdown in the myocardial infarction mouse model was conducted through adeno-associated virus injection, and cardiac function was evaluated by motion-mode echocardiography. The results showed that NRON was highly expressed in peripheral blood of AMI patients and H/R-stimulated H9c2 cells. NRON knockdown promoted cell viability and inhibited cell apoptosis of H/R-stimulated H9c2 cells. Meanwhile, NRON knockdown also significantly attenuated heart damage and improved cardiac function in an AMI mouse model. Furthermore, compared with si-normal control, NRON knockdown increased the levels of HIF-1α, p-AKT, p-mTOR, and p-ERK1/2. HIF-1α knockdown reversed the effects of NRON knockdown in H/R-stimulated-H9c2 cells damage. Overall, our study revealed that NRON knockdown alleviated H/R-induced cardiomyocyte apoptosis by upregulating HIF-1α expression, suggesting that NRON might be a novel therapeutic target for AMI.
- Open Access
- 28 January 2021
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (1) , e00714
Protective effect of glycyrrhizin on coronary microembolization‐induced myocardial dysfunction in rats
Coronary microembolization (CME)‐induced inflammation and cardiomyocyte apoptosis are two key factors contributing to CME‐induced myocardial dysfunction. High‐mobility group box‐1 (HMGB1) plays essential role in progression of CME‐induced injury and inhibition of HMGB1 has been shown to be protective. In present study, the potential effects of glycyrrhizin, a HMGB1 inhibitor, on CME‐induced myocardial dysfunction are evaluated. Using a rat model of CME, we administrated glycyrrhizin in rats prior to CME induction. The level of HMGB1, TNF‐α, iNOS, IL‐6, IL‐1β, cleaved caspase‐3, Bax, and Bcl‐2 were measured. The serum level of cardiac troponin I, creatine kinase, was detected. The cardiac function and cardiomyocyte apoptosis were evaluated. The activation of TLR4/NF‐κB signaling pathway was analyzed. Glycyrrhizin prevented CME‐induced production of HMGB1, TNF‐α, iNOS, IL‐6, and IL‐1β. Glycyrrhizin inhibited CME‐induced cardiomyocyte apoptosis and the expression of cleaved caspase‐3 and Bax, while enhanced the expression of Bcl‐2. Glycyrrhizin decreased cardiac troponin I and creatine kinase levels and improved cardiac function. Glycyrrhizin prevented the activation of HMGB1/TLR4/NF‐κB signaling pathway. Glycyrrhizin ameliorated myocardial dysfunction in CME rats by preventing inflammation and apoptosis of cardiomyocytes.
- 28 January 2021
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (1) , e00714
Open AccessProtective effect of glycyrrhizin on coronary microembolization‐induced myocardial dysfunction in rats
Coronary microembolization (CME)‐induced inflammation and cardiomyocyte apoptosis are two key factors contributing to CME‐induced myocardial dysfunction. High‐mobility group box‐1 (HMGB1) plays essential role in progression of CME‐induced injury and inhibition of HMGB1 has been shown to be protective. In present study, the potential effects of glycyrrhizin, a HMGB1 inhibitor, on CME‐induced myocardial dysfunction are evaluated. Using a rat model of CME, we administrated glycyrrhizin in rats prior to CME induction. The level of HMGB1, TNF‐α, iNOS, IL‐6, IL‐1β, cleaved caspase‐3, Bax, and Bcl‐2 were measured. The serum level of cardiac troponin I, creatine kinase, was detected. The cardiac function and cardiomyocyte apoptosis were evaluated. The activation of TLR4/NF‐κB signaling pathway was analyzed. Glycyrrhizin prevented CME‐induced production of HMGB1, TNF‐α, iNOS, IL‐6, and IL‐1β. Glycyrrhizin inhibited CME‐induced cardiomyocyte apoptosis and the expression of cleaved caspase‐3 and Bax, while enhanced the expression of Bcl‐2. Glycyrrhizin decreased cardiac troponin I and creatine kinase levels and improved cardiac function. Glycyrrhizin prevented the activation of HMGB1/TLR4/NF‐κB signaling pathway. Glycyrrhizin ameliorated myocardial dysfunction in CME rats by preventing inflammation and apoptosis of cardiomyocytes.
- Open Access
- 8 January 2021
- Published by Wiley in Journal of Diabetes Research
- Vol. 2021, 1-7
In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention
Although percutaneous coronary intervention (PCI) significantly improves the prognosis for myocardial infarction, the no-reflow phenomenon is still the major adverse complication of PCI leading to increased mortality, especially for the patients with ST-segment elevation myocardial infarction (STEMI) combined with diabetes. To reduce the occurrence of no-reflow, prognostic factors must be identified for no-reflow phenomenon before PCI. A total of 262 participants with acute STEMI and diabetes were recruited into our cardiovascular center and underwent primary PCI for the analyses of prognostic factors of no-reflow. The patients were divided into two groups according to thrombolysis in myocardial infarction (TIMI): the normal flow and no-reflow groups, and related factors were analyzed with different statistical methods. In the present investigation, the in-hospital peak glycemia was significantly higher in the no-reflow group than the normal flow group, while more narrowed vessels, higher level of initial TIMI flow, were observed in the patients of the no-reflow group. A multivariate logistic regression analysis further demonstrated that peak glycemia was an independent predictor for no-reflow in the diabetic patients with STEMI. Our data indicated the importance of the proper control of glucose before PCI for the diabetic patients with STEMI before PCI to reduce the occurrence of the no-reflow after operation.
- 8 January 2021
- Published by Wiley in Journal of Diabetes Research
- Vol. 2021, 1-7
Open AccessIn-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention
Although percutaneous coronary intervention (PCI) significantly improves the prognosis for myocardial infarction, the no-reflow phenomenon is still the major adverse complication of PCI leading to increased mortality, especially for the patients with ST-segment elevation myocardial infarction (STEMI) combined with diabetes. To reduce the occurrence of no-reflow, prognostic factors must be identified for no-reflow phenomenon before PCI. A total of 262 participants with acute STEMI and diabetes were recruited into our cardiovascular center and underwent primary PCI for the analyses of prognostic factors of no-reflow. The patients were divided into two groups according to thrombolysis in myocardial infarction (TIMI): the normal flow and no-reflow groups, and related factors were analyzed with different statistical methods. In the present investigation, the in-hospital peak glycemia was significantly higher in the no-reflow group than the normal flow group, while more narrowed vessels, higher level of initial TIMI flow, were observed in the patients of the no-reflow group. A multivariate logistic regression analysis further demonstrated that peak glycemia was an independent predictor for no-reflow in the diabetic patients with STEMI. Our data indicated the importance of the proper control of glucose before PCI for the diabetic patients with STEMI before PCI to reduce the occurrence of the no-reflow after operation.
- Open Access
- 26 December 2019
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 19 (1) , 1-4
A case presentation of patient from northern China with endomyocardial fibrosis
Background: Endomyocardial fibrosis (EMF) is a rare condition and a major cause of death in tropical countries. The etiology of EMF remains elusive, and no specific treatment has been developed yet, therefore it carries poor prognosis. Case presentation: An 81-year-old male Chinese patient with a history of long-standing exertional breathlessness, presented with worsening symptoms rapidly evolving to orthopnea. A proper specific treatment was prescribed to the patient in the following days, including diuretics, angiotensin-converting-enzyme inhibitor and beta blockers. The patient died of progressive multiple organ failure. Conclusion: Echocardiography is technically limited due to the acoustic shadowing as a result of the calcification. Chest computed tomography is a more accurate diagnostic tool to examine the anatomic distribution and extent of endomyocardial calcification in this rare case.
- 26 December 2019
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 19 (1) , 1-4
Open AccessA case presentation of patient from northern China with endomyocardial fibrosis
Background: Endomyocardial fibrosis (EMF) is a rare condition and a major cause of death in tropical countries. The etiology of EMF remains elusive, and no specific treatment has been developed yet, therefore it carries poor prognosis. Case presentation: An 81-year-old male Chinese patient with a history of long-standing exertional breathlessness, presented with worsening symptoms rapidly evolving to orthopnea. A proper specific treatment was prescribed to the patient in the following days, including diuretics, angiotensin-converting-enzyme inhibitor and beta blockers. The patient died of progressive multiple organ failure. Conclusion: Echocardiography is technically limited due to the acoustic shadowing as a result of the calcification. Chest computed tomography is a more accurate diagnostic tool to examine the anatomic distribution and extent of endomyocardial calcification in this rare case.
- Open Access
- 1 August 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (9) , e909
Circulating miR‐130 and its target PPAR‐γ may be potential biomarkers in patients of coronary artery disease with type 2 diabetes mellitus
Background: Patients of coronary artery disease (CAD) with type 2 diabetes mellitus (DM2) show increased mortality risk than CAD patients without DM2, while few biomarkers can be used to discriminate them.Methods: Fifty‐nine patients of CAD with DM2 (DM2‐CAD group), 79 patients of CAD without DM2 (CAD group), and 63 healthy control subjects were recruited. Circulating miR‐130 (miR‐130a and miR‐130b) and PPAR‐γ (peroxisome proliferator‐activated receptor gamma) were measured and their Pearson correlation was analyzed. 3′ UTR binding prediction and luciferase assay were used to determine the target relationship between miR‐130 and PPAR‐γ. Receiver operating characteristics (ROC) analysis was performed to test the discrimination ability of miR‐130 between DM2‐CAD and CAD groups.Results: miR‐130a and miR‐130b showed decreased expression in DM2‐CAD group when compared with the CAD group and health control. Both bioinformatics and luciferase assays showed that miR‐130 could bind the 3′ UTR of PPAR‐γ. Furthermore, miR‐130 negatively correlated with PPAR‐γ in both CAD and DM2‐CAD group in Pearson's coefficient analysis. Both miR‐130a and miR‐130b were able to discriminate DM2‐CAD group from CAD group and control subjects.Conclusion: Circulating miR‐130 may regulate the expression of PPAR‐γ and can be used as a biomarker to discriminate DM2‐CAD from CAD.
- 1 August 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (9) , e909
Open AccessCirculating miR‐130 and its target PPAR‐γ may be potential biomarkers in patients of coronary artery disease with type 2 diabetes mellitus
Background: Patients of coronary artery disease (CAD) with type 2 diabetes mellitus (DM2) show increased mortality risk than CAD patients without DM2, while few biomarkers can be used to discriminate them.Methods: Fifty‐nine patients of CAD with DM2 (DM2‐CAD group), 79 patients of CAD without DM2 (CAD group), and 63 healthy control subjects were recruited. Circulating miR‐130 (miR‐130a and miR‐130b) and PPAR‐γ (peroxisome proliferator‐activated receptor gamma) were measured and their Pearson correlation was analyzed. 3′ UTR binding prediction and luciferase assay were used to determine the target relationship between miR‐130 and PPAR‐γ. Receiver operating characteristics (ROC) analysis was performed to test the discrimination ability of miR‐130 between DM2‐CAD and CAD groups.Results: miR‐130a and miR‐130b showed decreased expression in DM2‐CAD group when compared with the CAD group and health control. Both bioinformatics and luciferase assays showed that miR‐130 could bind the 3′ UTR of PPAR‐γ. Furthermore, miR‐130 negatively correlated with PPAR‐γ in both CAD and DM2‐CAD group in Pearson's coefficient analysis. Both miR‐130a and miR‐130b were able to discriminate DM2‐CAD group from CAD group and control subjects.Conclusion: Circulating miR‐130 may regulate the expression of PPAR‐γ and can be used as a biomarker to discriminate DM2‐CAD from CAD.
- Open Access
- 22 November 2017
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 30 (4) , 406-412
Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats
This study aimed to exploit the potential therapeutic value of palmatine in treatment of cardiac hypertrophy and the underlying molecular mechanism. Rat hypertrophy model was established by intraperitoneal isoproterenol (ISO) injection. The hypertrophy was evaluated with cardiac hypertrophic parameters, hemodynamic parameters, lipid profile, and non-specific cardiac markers. The animals were intraperitoneally administrated with either palmatine or vehicle. The relative expressions of ANP, BNP, HDAC2, HDAC5, KLF4, and INPP5F transcripts were determined by real-time polymerase chain reaction (PCR). The relative protein levels of HDAC2, HDAC5, KLF4, and INPP5F were analyzed by immunoblotting. Palmatine treatment significantly attenuated ISO-induced hypertrophy in rats and elicited remarkable repressions in ANP, BNP, and HDAC2 transcriptions but not HDAC5. The downstream effector genes KLF4 and INPP5F were greatly restored in a dose-dependent manner in response to palmatine treatment. Our data demonstrated that palmatine possessed promising therapeutic potential against hypertrophy, which was mediated by modulation of HDAC2-KLF4/INPP5F pathway.
- 22 November 2017
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 30 (4) , 406-412
Open AccessPalmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats
This study aimed to exploit the potential therapeutic value of palmatine in treatment of cardiac hypertrophy and the underlying molecular mechanism. Rat hypertrophy model was established by intraperitoneal isoproterenol (ISO) injection. The hypertrophy was evaluated with cardiac hypertrophic parameters, hemodynamic parameters, lipid profile, and non-specific cardiac markers. The animals were intraperitoneally administrated with either palmatine or vehicle. The relative expressions of ANP, BNP, HDAC2, HDAC5, KLF4, and INPP5F transcripts were determined by real-time polymerase chain reaction (PCR). The relative protein levels of HDAC2, HDAC5, KLF4, and INPP5F were analyzed by immunoblotting. Palmatine treatment significantly attenuated ISO-induced hypertrophy in rats and elicited remarkable repressions in ANP, BNP, and HDAC2 transcriptions but not HDAC5. The downstream effector genes KLF4 and INPP5F were greatly restored in a dose-dependent manner in response to palmatine treatment. Our data demonstrated that palmatine possessed promising therapeutic potential against hypertrophy, which was mediated by modulation of HDAC2-KLF4/INPP5F pathway.